Suzanne Kyle

8.2k total citations · 1 hit paper
23 papers, 5.6k citations indexed

About

Suzanne Kyle is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Suzanne Kyle has authored 23 papers receiving a total of 5.6k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 19 papers in Molecular Biology and 3 papers in Genetics. Recurrent topics in Suzanne Kyle's work include PARP inhibition in cancer therapy (19 papers), DNA Repair Mechanisms (16 papers) and Cancer therapeutics and mechanisms (6 papers). Suzanne Kyle is often cited by papers focused on PARP inhibition in cancer therapy (19 papers), DNA Repair Mechanisms (16 papers) and Cancer therapeutics and mechanisms (6 papers). Suzanne Kyle collaborates with scholars based in United Kingdom, United States and Sweden. Suzanne Kyle's co-authors include Nicola J. Curtin, Huw D. Thomas, Thomas Helleday, Elena López‐Knowles, Niklas Schultz, Mark Meuth, Helen E. Bryant, Zdeněk Hostomský, David R. Newell and Barbara W. Durkacz and has published in prestigious journals such as Nature, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

Suzanne Kyle

23 papers receiving 5.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

2005 3.8k citations Helen E. Bryant, Niklas Schultz et al. Nature profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Suzanne Kyle United Kingdom	20	4.2k	4.2k	804	622	446	23	5.6k
Charlotte Knights United Kingdom	6	3.8k 0.9×	3.9k 0.9×	914 1.1×	770 1.2×	479 1.1×	13	5.4k
Huw D. Thomas United Kingdom	28	4.5k 1.1×	4.3k 1.0×	799 1.0×	801 1.3×	409 0.9×	64	6.2k
Damian A. Johnson United Kingdom	4	3.5k 0.8×	3.6k 0.8×	874 1.1×	802 1.3×	454 1.0×	4	4.9k
Ian Hickson United Kingdom	16	4.8k 1.1×	4.2k 1.0×	996 1.2×	1.0k 1.6×	456 1.0×	28	6.4k
Niklas Schultz Sweden	22	5.5k 1.3×	4.3k 1.0×	847 1.1×	1.0k 1.7×	339 0.8×	32	6.9k
Manuela Santarosa Italy	18	4.0k 0.9×	3.8k 0.9×	1.1k 1.3×	1.0k 1.7×	495 1.1×	32	5.7k
Jiuping Ji United States	21	3.2k 0.7×	3.7k 0.9×	583 0.7×	412 0.7×	481 1.1×	41	4.6k
Alan Lau United Kingdom	31	5.1k 1.2×	5.1k 1.2×	1.2k 1.5×	1.0k 1.7×	647 1.5×	61	7.3k
Nuala McCabe United Kingdom	19	5.1k 1.2×	5.0k 1.2×	1.3k 1.6×	1.2k 1.9×	672 1.5×	43	7.2k
David S. Boss Netherlands	14	2.5k 0.6×	3.1k 0.7×	939 1.2×	778 1.3×	713 1.6×	24	4.4k

Countries citing papers authored by Suzanne Kyle

Since Specialization

Citations

This map shows the geographic impact of Suzanne Kyle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suzanne Kyle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suzanne Kyle more than expected).

Fields of papers citing papers by Suzanne Kyle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suzanne Kyle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suzanne Kyle. The network helps show where Suzanne Kyle may publish in the future.

Co-authorship network of co-authors of Suzanne Kyle

This figure shows the co-authorship network connecting the top 25 collaborators of Suzanne Kyle. A scholar is included among the top collaborators of Suzanne Kyle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Suzanne Kyle. Suzanne Kyle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Almeida, Gilberto S., Ian Wilson, Huw D. Thomas, et al.. (2017). PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS. NMR in Biomedicine. 30(9). 15 indexed citations

Murray, J. C., Huw D. Thomas, P. Berry, et al.. (2014). Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules. British Journal of Cancer. 110(8). 1977–1984. 33 indexed citations

Batey, Michael A., Yan Zhao, Suzanne Kyle, et al.. (2013). Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer. Molecular Cancer Therapeutics. 12(6). 959–967. 113 indexed citations

Haagensen, Emma J., Suzanne Kyle, Gary Beale, R. J. Maxwell, & David R. Newell. (2012). The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition. British Journal of Cancer. 106(8). 1386–1394. 60 indexed citations

Ali, Majid, Huw D. Thomas, Suzanne Kyle, et al.. (2011). The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in Mice. Molecular Cancer Therapeutics. 10(12). 2320–2329. 43 indexed citations

Rowling, Emily J., Suzanne Kyle, Adam P. Hopkins, et al.. (2011). Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines. British Journal of Cancer. 105(3). 372–381. 152 indexed citations

Issaeva, Natalia, Huw D. Thomas, Janneke E. Jaspers, et al.. (2010). 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance. Cancer Research. 70(15). 6268–6276. 80 indexed citations

Mukhopadhyay, Asima, Ahmed Elattar, Sarah Wilkinson, et al.. (2010). Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors. Clinical Cancer Research. 16(8). 2344–2351. 207 indexed citations

Drew, Yvette, Evan A. Mulligan, Huw D. Thomas, et al.. (2010). Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2. JNCI Journal of the National Cancer Institute. 103(4). 334–346. 191 indexed citations

10.

Ali, Majid, Brian A. Telfer, Cian M. McCrudden, et al.. (2009). Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation In vivo ?. Clinical Cancer Research. 15(19). 6106–6112. 42 indexed citations

11.

Kyle, Suzanne, et al.. (2008). Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer. British Journal of Radiology. 81(special_issue_1). S6–S11. 30 indexed citations

12.

Thomas, Huw D., Christopher Calabrese, Michael A. Batey, et al.. (2007). Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Molecular Cancer Therapeutics. 6(3). 945–956. 233 indexed citations

13.

Bryant, Helen E., Niklas Schultz, Huw D. Thomas, et al.. (2005). Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 434(7035). 913–917. 3780 indexed citations breakdown →

14.

White, Alex W., Nicola J. Curtin, Brian Eastman, et al.. (2004). Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors. Bioorganic & Medicinal Chemistry Letters. 14(10). 2433–2437. 60 indexed citations

15.

Tikhe, Jayashree, Stephen E. Webber, Zdeněk Hostomský, et al.. (2004). Design, Synthesis, and Evaluation of 3,4-Dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-ones as Inhibitors of Poly(ADP-Ribose) Polymerase. Journal of Medicinal Chemistry. 47(22). 5467–5481. 33 indexed citations

16.

Curtin, Nicola J., Suzanne Kyle, Robert Griffin, et al.. (2000). Design and evaluation of novel potent inhibitors of poly (ADP-ribose) polymerase. Clinical Cancer Research. 1 indexed citations

17.

Boulton, Simon J., Suzanne Kyle, & Barbara W. Durkacz. (2000). Mechanisms of enhancement of cytotoxicity in etoposide and ionising radiation-treated cells by the protein kinase inhibitor wortmannin. European Journal of Cancer. 36(4). 535–541. 27 indexed citations

18.

Delaney, Carol A., Suzanne Kyle, Alex W. White, et al.. (2000). Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines.. PubMed. 6(7). 2860–7. 164 indexed citations

19.

Boulton, Simon J., et al.. (1997). Low nicotinamide mononucleotide adenylyltransferase activity in a tiazofurin-resistant cell line: effects on NAD metabolism and DNA repair. British Journal of Cancer. 76(7). 845–851. 19 indexed citations

20.

Kyle, Suzanne, et al.. (1996). Wortmannin is a potent inhibitor of DNA double strand break but not single strand break repair in Chinese hamster ovary cells. Carcinogenesis. 17(11). 2285–2290. 109 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact